Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 6Phase 3 4Phase 2/3 3Phase 1/2 2Phase 1 2

Status

Completed 11Recruiting 4Terminated 3Withdrawn 2Unknown 2Active not recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

durvalumab 2Gemcitabine 2Cisplatin 2zanidatamab 1pembrolizumab 1Oxaliplatin 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Gallbladder Neoplasms × Clear all
NCT07265674 2026-05-14

Beacon-BTC

J-Pharma Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06712420 2025-04-16

NEOGB

Rajiv Gandhi Cancer Institute & Research Center, India

Phase 3 Recruiting
114 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡